KalVista Pharmaceuticals (KALV) Income from Continuing Operations (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Income from Continuing Operations of 60139000.0 for Q3 2025, down 48.7% on a YoY basis from 117231482.96 in Q3 2024, and down 15.13% sequentially from 52234000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Income from Continuing Operations (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Income from Continuing Operations data on file, last reported at 60139000.0 in Q3 2025.
- For the quarter ending Q3 2025, Income from Continuing Operations fell 48.7% year-over-year to 60139000.0; the trailing twelve-month figure through Jul 2025 stood at 204876000.0 (down 158.97% YoY), and the FY2025 full-year result was 183452000.0, down 248.36% from the prior year.
- Income from Continuing Operations slipped to 60139000.0 in Q3 2025, from 52234000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 29334000.0 in Q2 2024 to a low of 60139000.0 in Q3 2025.
- A 5-year average of 33805666.67 and a median of 37629000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 196.8% in 2024 and plunged 278.07% in 2025, its largest moves.
- Tracing KALV's Income from Continuing Operations over 5 years: stood at 33349000.0 in 2021, then retreated by 11.62% to 37225000.0 in 2022, then fell by 4.7% to 38976000.0 in 2023, then plunged by 33.57% to 52060000.0 in 2024, then decreased by 15.52% to 60139000.0 in 2025.
- Business Quant data shows KALV's Income from Continuing Operations at 60139000.0 in Q3 2025, 52234000.0 in Q2 2025, and 52060000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -60.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -60.14 Mn |
| Apr 30, 2025 | -52.23 Mn |
| Oct 31, 2024 | -52.06 Mn |
| Jul 31, 2024 | -40.44 Mn |
| Apr 30, 2024 | 29.33 Mn |
| Jan 31, 2024 | -29.03 Mn |
| Oct 31, 2023 | -38.98 Mn |
| Jul 31, 2023 | -38.84 Mn |
| Apr 30, 2023 | -30.30 Mn |
| Jan 31, 2023 | -37.40 Mn |
| Oct 31, 2022 | -37.23 Mn |
| Jul 31, 2022 | -38.11 Mn |
| Apr 30, 2022 | -57.36 Mn |
| Jan 31, 2022 | -37.86 Mn |
| Oct 31, 2021 | -33.35 Mn |
| Jul 31, 2021 | -22.09 Mn |
| Apr 30, 2021 | -19.37 Mn |
| Jan 31, 2021 | -13.05 Mn |
| Oct 31, 2020 | -13.28 Mn |
| Jul 31, 2020 | -14.78 Mn |